Related Experiment Video

Updated: Aug 19, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy

Andreea Parosanu1, Ioana Miruna Stanciu2, Cristina Pirlog1

  • 1Oncology, Elias Emergency University Hospital, Bucharest, ROU.

Cureus
|December 1, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show promise in cancer treatment, but not all patients respond. Identifying biomarkers for kidney cancer patients is crucial for predicting response to this immunotherapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Research

Background:

  • Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy.
  • Despite their efficacy in various cancers, a substantial number of patients exhibit resistance to ICIs.
  • Predicting response to immunotherapy is essential for optimizing treatment strategies in renal cell carcinoma.

Purpose of the Study:

  • To review existing research on potential biomarkers for predicting response to ICIs in renal cell carcinoma.
  • To highlight the importance of identifying predictive factors for immunotherapy in kidney cancer.

Main Methods:

  • Literature review of studies investigating biomarkers for ICI response in renal cell carcinoma.
  • Analysis of current research on predictive factors in immuno-oncology.

Main Results:

  • The review synthesizes findings on various potential biomarkers.
  • Current research indicates a need for validated predictive markers for ICI therapy in kidney cancer.

Conclusions:

  • Identifying reliable biomarkers is critical for patient selection and treatment personalization in renal cell carcinoma.
  • Further research is needed to establish robust predictive markers for immunotherapy response.
Keywords:
immune check-point inhibitorpredictive risk factorsrenal cell carcinoma (rcc)risk factor modelserum biomarkers

More Related Videos

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

12.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
630